Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026.
New research shows sotagliflozin is the only drug in its class to demonstrate these results. Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia®▼(finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the ...
Risk for a composite heart failure outcome was reduced by 22% with oral semaglutide in heart failure patients with type 2 diabetes and certain comorbidities, a secondary analysis of a ...
In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type ...
New drugs and a growing awareness of the common condition offer hope for patients. By Nina Agrawal Ann Ramirez first noticed something was wrong when, at age 48, she started waking up in the middle of ...
Heart disease continues to stand as the No. 1 cause of death in the United States. Coronary heart disease, the most common type of heart disease in the U.S., was responsible for the deaths of nearly ...
Hosted on MSN
Master nursing pharmacology without the overwhelm
Pharmacology can feel like a mountain for nursing students, but with the right tools, strategies, and mindset, it becomes manageable—and even empowering. From drug suffix hacks to the 7 Rights of safe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results